BACKGROUND The presence of human leukocyte antigen donor-specific antibodies (DSAs) increases the risk of graft failure in T-cell-replete haploidentical hematopoietic stem cell transplantation (haplo-HSCT) CASE REPORT A 49-year-old female with high-risk acute myeloid leukemia in first complete remission received a haplo-HSCT from her daughter. Pretransplant recipient screening examination showed high DSAs levels against unshared class I leukocyte antigens. RESULTS The patient underwent a desensitization program consisting of plasma exchange (PEX), polyvalent intravenous (IV) immunoglobulins, and IV tacrolimus and mycophenolate mofetil (MMF). This protocol resulted in the disappearance of the DSA anti HLA B41. Engraftment was prompt with stable full donor chimerism. CONCLUSIONS This case report suggests that the adopted scheme is safe for reducing DSA levels and facilitating donor engraftment in patients scheduled for haplo-HSCT.
Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation / S. Bramanti, A. Nocco, E. Mauro, G. Milone, L. Morabito, B. Sarina, R. Crocchiolo, I. Timofeeva, R. Capizzuto, C. Carlo Stella, A. Santoro, L. Castagna. - In: TRANSFUSION. - ISSN 0041-1132. - 56:5(2016 May), pp. 1096-1100. [10.1111/trf.13523]
Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation
C. Carlo Stella;
2016
Abstract
BACKGROUND The presence of human leukocyte antigen donor-specific antibodies (DSAs) increases the risk of graft failure in T-cell-replete haploidentical hematopoietic stem cell transplantation (haplo-HSCT) CASE REPORT A 49-year-old female with high-risk acute myeloid leukemia in first complete remission received a haplo-HSCT from her daughter. Pretransplant recipient screening examination showed high DSAs levels against unshared class I leukocyte antigens. RESULTS The patient underwent a desensitization program consisting of plasma exchange (PEX), polyvalent intravenous (IV) immunoglobulins, and IV tacrolimus and mycophenolate mofetil (MMF). This protocol resulted in the disappearance of the DSA anti HLA B41. Engraftment was prompt with stable full donor chimerism. CONCLUSIONS This case report suggests that the adopted scheme is safe for reducing DSA levels and facilitating donor engraftment in patients scheduled for haplo-HSCT.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bramanti_et_al_Transfusion_2016.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
94.35 kB
Formato
Adobe PDF
|
94.35 kB | Adobe PDF | [it] Default value: Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR




